Trial Profile
The Role of Bacterial Overgrowth and Delayed Intestinal Transit in Hepatic Encephalopathy. Phase A: Breath Testing and Colonic Transit in Hepatic Encephalopathy. Phase B: A Randomized Double Blind, Placebo Controlled Trial of Rifaximin for Hepatic Encephalopathy
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 15 May 2019
Price :
$35
*
At a glance
- Drugs Rifaximin (Primary)
- Indications Hepatic encephalopathy
- Focus Therapeutic Use
- 23 Jul 2018 According to ClinicalTrials.gov, the recruitment status of this study is unknown because the information has not been verified recently (last verified November 2010).
- 13 Jul 2018 According to a Bausch Health Companies media release, Valeant Pharmaceuticals International changed its name to Bausch Health Companies.
- 24 Nov 2015 New trial record